Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Psychiatry

Sec. Addictive Disorders

Volume 16 - 2025 | doi: 10.3389/fpsyt.2025.1503564

This article is part of the Research TopicNeuropsychological Mechanisms Underlying Risk, Resilience, and Intervention Response in Youth Substance UseView all articles

Burden and trends of drug use disorders in young adults: Global Insights from GBD 2021

Provisionally accepted
  • 1Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China
  • 2State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center (SYSUCC), Guanghzou, Guangdong, China
  • 3Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China

The final, formatted version of the article will be published soon.

Background: Drug use disorders (DUDs) is a serious global health crisis, particularly affecting adolescents and young people. The increasing prevalence of DUDs has led to the development of chronic diseases, including cancer, although it has significant impacts on health and life, it is often overlooked in research. Method: This study utilized GBD 2021 data to assess the burden of four drug use disorders in the young adult population. The data, covering 1991 to 2021, included metrics such as age-sex-year incidence, prevalence, deaths, and disability-adjusted life years (DALYs). Age-standardized rates were used for comparing burden across years and regions, and joinpoint analysis evaluated trends. The Bayesian Age-Period-Cohort model was employed to project future burden. The study also examined the relationship between DUDs burden and socio-economic conditions using the Social Development Index (SDI) and stratified data by WHO regions. Additionally, population attributable fractions were calculated within the GBD comparative risk assessment framework. Results: Cannabis use disorder (CUDs) emerged as the most prevalent, the ASPR was 617.22/100,000 in 2021. The highest age-standardized mortality rates (ASMR) and age-standardized DALYs rates (ASDR) was observed in OUDs, at (1.46 [1.37-1.55]) and (236.61[185.21-292.47]), respectively. The region of the Americas accounted for the largest proportion of this burden. Opioid use disorders (OUDs) exhibited a notable rising trend, with the age-standardized prevalence rate (ASPR) of 359.62/100,000 in 2021, with a concentration primarily in the European region and the region of the Americas. Male had a higher burden of DUDs than female in the young adults. The burden of DUDs was mainly concentrated under the age of 25, especially CUDs and OUDs. The ASMR and ASDR of DUDs also showed significant growth trends in high SDI areas. Drug use's contribution to cancer risk, particularly liver cancer due to hepatitis C virus (HCV), had been progressively increasing. Conclusions: The burden of OUDs and CUDs, continued to escalate annually, especially among young adult males who face heightened risks. Notably, drug use is increasingly contributing to liver cancer mortality and DALYs, emphasizing the urgency of interventions. This study provides evidence for evaluating the burden transfer between different demographic data.

Keywords: age-period-cohort study, Drug use disorder, Global Burden of Diseases, Opioid use disorders, Cannabis use disorders

Received: 29 Sep 2024; Accepted: 26 Aug 2025.

Copyright: © 2025 Su, Fan, Quan, Kan, Liu, Zhang and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Bei Zhang, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China
Yuanyuan Huang, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.